MedTrace Logo

Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer

NCT03613597 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2020-02-05

No results posted yet for this study

Summary

This randomized phase II study compare survival outcomes and toxicity of two chemotherapy regimens (etoposide plus lobaplatin or etoposide plus cisplatin) in combination with concurrent thoracic radiation therapy (TRT) for limited stage small cell lung cancer.

Conditions

  • Small-cell Lung Cancer

Interventions

DRUG

etoposide plus lobaplatin

Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus lobaplatin

DRUG

etoposide plus cisplatin

Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus Cisplatin

Sponsors & Collaborators

  • Guizhou Medical University

    lead OTHER

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2021-01-01
Completion
2022-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03613597 on ClinicalTrials.gov